Dr. Rini on Pembrolizumab Plus Axitinib in RCC

Brian I. Rini, MD
Published: Tuesday, Jun 13, 2017



Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses a phase I study of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

The field of kidney cancer has several clinical trials combining VEGF-targeted agents and immunotherapies. While VEGF-targeted therapies are the standard of care, PD-1 inhibitors are also making headway in the landscape.

Preclinical data have been very compelling, Rini explains. A trial of 52 previously untreated patients with RCC who received the combination of pembrolizumab and axitinib demonstrated an overall response rate of 71%. This is about 30% higher than any other activity reported in the RCC field to date, he adds.


Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses a phase I study of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

The field of kidney cancer has several clinical trials combining VEGF-targeted agents and immunotherapies. While VEGF-targeted therapies are the standard of care, PD-1 inhibitors are also making headway in the landscape.

Preclinical data have been very compelling, Rini explains. A trial of 52 previously untreated patients with RCC who received the combination of pembrolizumab and axitinib demonstrated an overall response rate of 71%. This is about 30% higher than any other activity reported in the RCC field to date, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x